Abstract
Preimplantation genetic testing for aneuploidy (PGT-A) was developed to prevent transferring embryos with chromosomal abnormalities. However, current genetic testing is sensitive enough to detect mosaic abnormalities, or non-uniform chromosomal copy number differences within a subset of trophectoderm cells. An absolute threshold for clinically significant mosaicism remains poorly defined and clinics differ in their management of mosaic embryo results. Here we share our efforts to uncover clinically relevant features of mosaicism via in depth analysis of a multinational database.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
